Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re
CheqUp and WeightWatchers Announce Strategic Partnership to Support Growing Use of GLP-1 Medications in the UK
02:00am, Thursday, 22'nd May 2025
Partnership Provides CheqUp Members Access to WeightWatchers' Proven GLP-1 Companion Programme to Aid in Achieving Superior and Sustainable Results Partnership Provides CheqUp Members Access to Weight
Pepsi: Forget GLP-1 And Dividend Cuts, These Are The Real Reasons Why It's Crashing
09:00am, Saturday, 17'th May 2025
Pepsi's slump is mainly due to aggressive price hikes and high T-bond yields, not diworsification or health trends. Core profitability and capital efficiency remain strong; dividend sustainability con
Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adh
3 Refining & Marketing MLPs Poised to Defy Bearish Trends
01:21pm, Friday, 16'th May 2025
Following a careful analysis of the Zacks Oil and Gas - Refining & Marketing MLP industry, we advise focusing on companies like TRGP, SUN and GLP.
Bullish Case for These Energy Stocks: GLP, NFG, EPSN
05:15pm, Thursday, 15'th May 2025
Global Partners, National Fuel Gas Company and Epsilon Energy represent some of the most compelling stocks in the now attractive energy market.
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
04:05pm, Tuesday, 13'th May 2025
REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update
04:05pm, Tuesday, 13'th May 2025
- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration
Global Partners LP Common Units (GLP) Q1 2025 Earnings Call Transcript
01:16pm, Thursday, 08'th May 2025
Global Partners LP Common Units (NYSE:GLP ) Q1 2025 Earnings Conference Call May 8, 2025 10:00 AM ET Company Participants Sean Geary - CLO and Secretary Eric Slifka - President and CEO Gregory Hanson
BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for
GLP-1 competition heats up: Novo Nordisk CEO talks Wegovy, CVS deal, earnings
02:30pm, Wednesday, 07'th May 2025
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94).
WeightWatchers Files for Bankruptcy after losing out to GLP-1 Drugs
01:59pm, Wednesday, 07'th May 2025
Get more equity coverage like this on the Stock Movers podcast from Bloomberg, featuring five-minute episodes on the winners and losers in the stock market. Subscribe here: https://link.podtrac.com/h0
Hims & Hers Shows It's More Than Just GLP-1 Drugs
08:54am, Wednesday, 07'th May 2025
Hims & Hers Health (HIMS) released first-quarter earnings after the closing bell on Monday and saw shares surge on the robust numbers.
ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-a
WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal
